Potential inhibitor for blocking binding between ACE2 and SARS-CoV-2 spike protein with mutations

• DOI: 10.1016/j.biopha.2022.112802
• Publication Date: 2022-03-09T18:01:11Z
• Authors: Ming-Shao Tsai; Wei-Tai Shih; Yao-Hsu Yang; Yu-Shih Lin; Geng-He Chang; Cheng-Ming Hsu; Reming-Albert Yeh; Li-Hsin Shu; Yu-Ching Cheng; Hung-Te Liu; Yu-Huei Wu; Yu-Heng Wu; Rou-Chen Shen; Ching-Yuan Wu
• Keywords: Pandemic; Infectivity; Coronavirus

At the time of writing, more than 440 million confirmed coronavirus disease 2019 (COVID-19) cases and 5.97 COVID-19 deaths worldwide have been reported by World Health Organization since start outbreak pandemic in Wuhan, China. During pandemic, many variants SARS-CoV-2 arisen because high mutation rates. N501Y, E484K, K417N, K417T, L452R T478K receptor binding domain (RBD) region may increase infectivity several SARS-CoV-2. In this study, we discovered that GB-1, developed from Chiehyuan herbal formula which obtained Tian Shang Sheng Mu Chiayi Puzi Peitian Temple, can inhibit between ACE2 RBD with Wuhan type, K417N-E484K-N501Y L452R-T478K mutation. addition, GB-1 inhibited a single (E484K or N501Y), except K417N compositions glycyrrhizic acid Our results suggest could be potential candidate for prophylaxis different infection its inhibition mutations (L452R-T478K, K417N-E484K-N501Y, N501Y E484K).